CDC25C and breast cancer: These methods have been involved with biomarkers not too dissimilar to the cell cycle marker CDC25 in cancers affecting large swathes of the population, including oesophageal squamous cell carcinoma (Liu et al., 2023), breast cancer (Greenwalt et al., 2020) and colorectal and bladder cancers (Ciardiello et al., 2022; Kong et al., 2022) and gastric cancers (Lee et al., 2019).